All Updates

All Updates

icon
Filter
Partnerships
QIAGEN expands collaboration with AstraZeneca for companion diagnostics in chronic diseases
Precision Medicine
Aug 28, 2024
This week:
Management news
6K Additive awarded project to develop C-103 powder for additive manufacturing
Additive Manufacturing
Sep 27, 2024
Partnerships
WAAM3D partners with Innovative Space Carrier, Cranfield University, and Aichi Sangyo for space transport development
Additive Manufacturing
Sep 19, 2024
Product updates
Akselos introduces software for FPSO monitoring
Digital Twin
Yesterday
Funding
Operant AI raises USD 10 million in Series A funding to boost runtime protection
Next-gen Cybersecurity
Yesterday
Funding
Aembit raises USD 25 million in Series A funding to advance IAM solutions
Identity & Access Management
Yesterday
Product updates
Saviynt launches Intelligence Suite for identity security
Identity & Access Management
Yesterday
Geographic expansion
Partnerships
FarmWise partners with RDO Equipment Co. to expand AI-powered weeding technology for vegetable growers
Smart Farming
Yesterday
Management news
Alberta Food Security Inc. receives USD 5 million order for indoor farming technology
Vertical Farming
Yesterday
Partnerships
AutoStore enhances microfulfilment offering with new grid capabilities and multi-temperature solution
Logistics Tech
Yesterday
Product updates
OpenAI launches o1, a self-fact-checking AI model
Generative AI Applications
Yesterday
Precision Medicine

Precision Medicine

Aug 28, 2024

QIAGEN expands collaboration with AstraZeneca for companion diagnostics in chronic diseases

Partnerships

  • QIAGEN has expanded its collaboration with AstraZeneca to create companion diagnostics for AstraZeneca's forthcoming chronic disease treatments.

  • According to the partnership, QIAGEN will create and validate a genotyping assay using its QIAstat-Dx testing platform. It uses single-use cartridges with built-in sample processing, onboard reagents, and multiplex real-time PCR to detect and differentiate between multiple biomarkers, claiming to provide results within an hour.

  • This will enable medical professionals to carry out genotyping when patients undergo regular clinical examinations and make decisions concerning patient suitability for AstraZeneca's genome-targeted medicines.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.